Phase 1 Trial of Ebola Vaccine in Mali
A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.
Sponsor: Leidos Biomedical Research, Inc.
This PHASE1 trial investigates Ebola Virus Disease and Hemorrhagic Fever and is currently completed. Leidos Biomedical Research, Inc. leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Leidos Biomedical Research, Inc.
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Maryland, Baltimore
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .